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CASE REPORT Open Access
Autoimmune haemolytic anaemia associated
with epstein barr virus infection as a severe late
complication after kidney transplantation and
successful treatment with rituximab: case report
Alexander J Hamilton1,2, Lynsey H Webb1, Jennifer K Williams1, Richard J D’Souza1, Loretta SP Ngu3
and Jason Moore1*
Abstract
Background: Autoimmune haemolytic anaemia (AIHA) is a rare complication following kidney transplantation and
usually occurs early in its course. It is characterised by autoantibodies or alloantibodies directed against red blood
cells (RBCs).
Case presentation: We describe a 44 year old woman who presented 5 years after kidney transplantation with
profound transfusion dependent warm AIHA. Investigations confirmed an IgG autoantibody against RBCs and high
titre Epstein-Barr virus (EBV) viraemia. The patient was at higher risk for EBV disease being seronegative at the time
of transplantation but had detectable EBV capsid IgG antibody at the time of presentation. The haemolysis was
refractory to high dose steroid and intravenous immunoglobulin. There was a rapid and complete resolution of
both the anaemia and the viraemia following rituximab therapy, with no adverse events. Twenty-six units of blood
were required during the course of treatment.
Conclusions: To our knowledge this is the first reported case of EBV associated AIHA in a renal transplant recipient.
It highlights a rare pathology associated with post-transplant EBV infection, of broad interest to transplant physicians,
haematologists, and microbiologists, and the effective novel use of monoclonal anti-CD20 therapy.
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Background
Autoimmune haemolytic anaemia (AIHA) is an immune
disease characterised by antibodies directed against au-
tologous red blood cells (RBCs). Typically patients ex-
hibit anaemia with reticulocytosis, spherocytes and
polychromasia on the blood film with a positive direct
antiglobulin test (DAT) which is the hallmark [1], in
addition there is often increased unconjugated serum
bilirubin and elevated serum lactate dehydrogenase
(LDH). The antibodies can be subdivided into “warm” or
“cold” agglutinins depending on the thermal range of ac-
tivity [2] and the subsequent anaemia can be profound
and life threatening leading to large transfusion require-
ments. The aetiology is unknown, categorised either as
primary (idiopathic) or secondary when associated with
malignancy (in particular chronic lymphocytic leukae-
mia), connective tissue and inflammatory diseases, infec-
tions (both viral and mycoplasma associated with a cold
AIHA) [2, 3], or drugs (e.g. purine analogues and alkylat-
ing agents) [4, 5]. Alloantibody can also lead to haemoly-
sis post haematopoietic stem cell transplant, solid organ
transplant (i.e. passenger B lymphocyte syndrome), preg-
nancy and after transfusion [6].
Epstein-Barr virus is one of the eight human herpes vi-
ruses, and common in humans. In the United States, by
the age of 40 as many as 95 % of adults have been in-
fected with EBV. Infants (after maternal antibody protec-
tion has disappeared) and children have asymptomatic
* Correspondence: jason.moore3@nhs.net
1Department of Nephrology, Royal Devon and Exeter NHS Foundation Trust,
Exeter, UK
Full list of author information is available at the end of the article
© 2015 Hamilton et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Hamilton et al. BMC Nephrology  (2015) 16:108 
DOI 10.1186/s12882-015-0096-3
or mild disease. In adolescence or young adults, EBV
causes infectious mononucleosis in up to 50 %. Symp-
toms of infectious mononucleosis are commonly fever,
sore throat, and lymphadenopathy and are almost never
fatal. EBV then establishes a lifelong dormant infection
in B cells [7]. It is a carcinogenic virus associated with
Burkitt’s lymphoma, Hodgkin’s disease and nasopharyn-
geal carcinoma [8]. After transplantation EBV disease
can present with varied manifestations, including non-
specific febrile illness, gastroenteritis, hepatitis, mimick-
ing other viral infections, and most seriously post-
transplant lymphoproliferative disorder (PTLD) [9]. It
remains unclear why EBV causes autoimmune disease.
IgM antibodies to autoantigens are normally present in
the plasma at low non-pathologic titre. It has been
suggested that the B-cell clones that normally pro-
duce these autoantibodies are altered to produce IgG
antibodies in high and pathogenic levels in AIHA
[10]. Alternatively, defective control of IgG auto
reactivity by autologous IgM [11] or altered T-cell
function [12] has been proposed.
AIHA after solid organ transplantation has been re-
ported infrequently [13] and usually occurs early in the
course [14]. In this report, we describe a severe and late
presentation in the context of donor associated EBV
viraemia, the treatment and use of novel therapy.
Case presentation
In January 2013 a 44 year old white female presented to
our institution with malaise, exertional breathlessness,
night sweats and a headache. She had received a pre-
emptive deceased donor kidney transplant 5 years earl-
ier. The kidney characteristics were donation after circu-
latory death [DCD], human leucocyte antigen (HLA)
mismatch A1:B1:DR1, cytomegalovirus (CMV) serology
of both donor and recipient were negative but Epstein-
Barr virus (EBV) serology of the donor was positive
whereas the recipient was negative. The aetiology of end
stage renal disease was likely congenital, initial presenta-
tion was with advanced chronic kidney disease and a
single functioning kidney. The only baseline comorbidity
was congenital nystagmus. Primary graft function was
excellent and stabilised with serum creatinine 90 μmol/L
[1.0 mg/dL] and eGFR 60 ml/min/1.73 m2. Induction
immunosuppression was with basiliximab and mainten-
ance was tacrolimus, mycophenolate mofetil and pred-
nisolone, as per local protocols. She had been treated
with valganciclovir for CMV viraemia at 3 months and
mycophenolate was electively withdrawn in line with in-
stitutional protocol after 7 months. The patient contin-
ued on dual immunosuppressive therapy thereafter and
there were no episodes of acute rejection. Otherwise she
had an uneventful first 5 years except for cervical intrae-
pithelial neoplasia grade 1 and acne rosacea.
On examination she was pale, jaundiced and tachycar-
dic, with dark urine. There was no lymphadenopathy.
All investigations are shown in Additional file 1: Table
S1. They demonstrated a severe anaemia (haemoglobin
57 g/L) with parameters consistent with haemolysis.
DAT was positive confirming a warm agglutinin AIHA.
She required blood transfusion support and was initially
treated with high dose prednisolone (1 mg/kg) with little
effect. A 5 day course of intravenous immunoglobulin
(0.4 g/kg/day) was started on day 9. At this point a high
serum titre of EBV (538355 copies/ml) was detected
with serology suggesting this was reactivation from pre-
vious exposure to donor virus and not a primary infec-
tion (see Additional file 1: Table S1). She went on to
have a total body CT scan which detected no abnormal
lymphadenopathy and a bone marrow aspirate and tre-
phine was consistent with haemolysis and no evidence
of a lymphoproliferative disorder. Tacrolimus was con-
verted to sirolimus on day 28. After an initial fall in
serum EBV load there was a deterioration in clinical
state with increasing transfusion requirements followed
by an increase in EBV load. The patient was given rituxi-
mab 375 mg/m2 on day 30, followed by a further three
weekly doses. At the beginning of the treatment course
she had received 16 units of blood and the EBV viral
load was 268649 copies/ml. After the fourth dose of ri-
tuximab there was a significant decline in transfusion re-
quirement and the EBV viral load had fallen to
undetectable levels. Seven transfusions were required
during the rituximab course and three following the
course. Her serial haemoglobin, LDH, EBV viral load, ri-
tuximab doses and transfusions are shown in Fig. 1. She
had achieved complete remission 2 weeks after starting
the rituximab. There was no deleterious effect on graft
function and no adverse drug events were noted. In total
she required 26 units of blood with significant iron
overload, the serum ferritin rose to 2850 μg/L which
had fallen to 950 μg/L 12 months after remission.
Despite the acute illness graft function was un-
changed and she remains well on prednisolone and
sirolimus immunosuppression with no recurrence of
EBV viraemia or anaemia.
Discussion
In this case severe haemolysis secondary to a warm ag-
glutinin IgG antibody presented five years after kidney
transplantation and was associated with a high titre EBV
viraemia. Although the association between EBV pre-
senting as infectious mononucleosis and AIHA is well
established in the general population [7] surprisingly this
has not been reported after kidney transplantation. Our
patient had no evidence of lymphadenopathy. The sero-
logical investigations of a positive anti-EBV capsid IgG
antibody in our patient would suggest exposure more
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than three months prior to presentation and the patient
was at higher risk with a negative serostatus at the time
of transplantation. It is very possible that the patient had
been asymptomatically viraemic earlier in the transplant
course but we would not have detected this with no
protocol for nucleic acid testing (NAT) more than one
year post transplantation. A recent report suggests my-
cophenolate use post transplantation may well be associ-
ated with less EBV DNAaemia and our patient was not
taking an anti-proliferative agent [15].
There were clinical concerns in our case about the
lack of response to initial therapy, with steroids and
intravenous immunoglobulin, and the possibility of a
developing PTLD, therefore conversion to sirolimus and
rituximab treatment was undertaken. Sirolimus rescue
for tacrolimus-associated post-transplant autoimmune
haemolytic anaemia has been successfully reported [16],
and the evidence base is growing for its use in PTLD
and post-transplant malignancy [17, 18]. Multiple case
studies and retrospective reports have indicated success
with use of the monoclonal anti-CD20 antibody rituxi-
mab in both adults and children with resistant idiopathic
AIHA and EBV associated AIHA post haemopoietic
stem cell transplantation [19]. In the latter the mechan-
ism of action is felt to be the elimination of EBV infected
B cells. The effectiveness of this strategy in our case was
dramatic and well tolerated.
The adverse effects of multiple transfusions in this
case are yet to be quantified but they are potentially very
significant due to iron overload and HLA sensitisation.
Clearly the earlier the haemolysis is stopped the better.
International guidelines focus on EBV monitoring
(NAT) in the first year post transplantation, KDIGO rec-
ommend monthly monitoring for high risk individuals
(seronegative) from 3–6 months (the most common
period for primary EBV infection), then every 3 months
up to 1 year with reduction of immunosuppression when
titres rise [20]. Based upon a single case report, we do
not believe the long term monitoring of all seronegative/
high risk individuals to be an effective or practical
strategy in the avoidance of such a scenario. The ab-
sence of this presentation from the transplant litera-
ture to date indicates it is likely to be a rare
phenomenon but the effective safe intervention of ri-
tuximab warrants awareness.
For the practising nephrologist, this case is important in
highlighting the potential for a belated, life-threatening
situation associated with a common virus exposed to the
patient following the act of deceased donor kidney trans-
plantation; most importantly it demonstrates the failure of
Fig. 1 Serial haemoglobin, LDH and EBV viral load and response to Rituximab therapy
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conventional first line therapy leading to the rapid suc-
cessful use of a novel treatment.
Conclusion
To our knowledge this is the first report of AIHA associ-
ated with EBV viraemia post kidney transplantation. The
AIHA was unresponsive to conventional management,
however full resolution of haemolysis and viraemia was
achieved with rituximab treatment most likely by elimin-
ating the EBV infected B cells.
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